Results 161 to 170 of about 55,011 (304)
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki +3 more
wiley +1 more source
What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review [PDF]
Jared Berndt +2 more
openalex +1 more source
Rethinking control‐IQ+ technology: Simple strategies for easy optimization
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah +5 more
wiley +1 more source
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami +16 more
wiley +1 more source
History of glucagon-like peptide-1 receptor agonists
Radwan Darwish +2 more
doaj +1 more source
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source

